Exhibiting at Middle East Poultry Expo 2025

Vaxxinova International B.V., headquartered in Nijmegen, Netherlands, is a prominent global provider of veterinary vaccines and diagnostic services. As a subsidiary of the German EW Group, Vaxxinova operates as a central hub for biotechnology innovation aimed at animal health, with a special focus on preventive health management in livestock and aquaculture.

Core Business and Specialization

Vaxxinova specializes in the development, production, and distribution of vaccines and diagnostic solutions for poultry, cattle, swine, and aquaculture. The company’s strength lies in its research-driven approach and the use of proprietary technologies such as SRP® (Siderophore Receptor and Porin) for creating advanced vaccines that elicit strong immune responses while reducing pathogenic side effects.

Key Specializations:

• Proprietary SRP® Vaccine Technology
• Autogenous Vaccines Tailored to Client Needs
• Comprehensive Diagnostic Services and Custom Vaccination Programs
• Regulatory-Compliant Production Across Multiple Continents

Product and Service Offerings

Vaxxinova offers a robust portfolio of registered and custom-developed vaccines and diagnostics, including:

• Poultry Vaccines: Inactivated and live vaccines for respiratory and enteric diseases.
• Cattle Vaccines: Including VAXXON®SRP® Klebsiella and VAXXON®SRP® Salmonella.
• Swine Vaccines: Registered and autogenous vaccines for endemic farm pathogens.
• Aquaculture Vaccines: Formulations for salmon, tilapia, and other commercial fish species.
• Autogenous Vaccines: Farm-specific bacterial and viral solutions.
• Diagnostics: Disease monitoring, pathogen identification, and laboratory consultation.

These solutions are supported by strong R&D and are deployed across diverse geographies with tailored programs for local disease prevalence.

Global Reach and Operational Footprint

Vaxxinova operates production and diagnostic facilities across 10 countries including Brazil, Chile, Germany, Italy, Japan, Jordan, Norway, the Netherlands, and the United States. It serves customers in more than 50 countries, making it a significant global player in veterinary health.

• Global Diagnostic Labs: Including the Novio Tech Campus in Nijmegen.
• Production Sites: Located in Brazil, Norway, Germany, and the U.S.
• Field Operations and Commercial Teams: Across Europe, Latin America, Asia, and the Middle East.

Infrastructure and R&D Capabilities

The Nijmegen facility is a core research and diagnostics hub. The infrastructure includes:

• State-of-the-Art Laboratories: For microbiology, virology, molecular diagnostics.
• GMP-Compliant Production Plants: For high-volume and autogenous vaccine production.
• SRP® Platform: Used for developing vaccines with less antigenic clutter and better immune targeting.
• Cross-Species Expertise: Supporting poultry, bovine, swine, and aquaculture sectors.

Financial Strength and Industry Recognition

As a part of the EW Group, a global agribusiness conglomerate, Vaxxinova benefits from robust financial backing and access to extensive industry networks. While specific revenue figures are proprietary, industry estimates place Vaxxinova among the top-tier biotech players in the animal health segment with a strong CAGR over the last five years.

Certifications and Compliance

Vaxxinova’s operations are certified to meet international standards:

• GMP – Good Manufacturing Practice
• GLP – Good Laboratory Practice
• ISO 9001 and ISO 17025
• European Medicines Agency (EMA) and USDA Certified Products

Client Testimonials and Market Impact

Veterinarians and integrators recognize Vaxxinova for its adaptability and science-based solutions. Its autogenous vaccine programs are particularly praised for their farm-specific customization and rapid delivery.

“Vaxxinova's diagnostics and SRP® vaccines have helped us control endemic salmonella and klebsiella outbreaks. Their science-first model is a game changer.” – Dr. Elena Rossi, Veterinary Consultant, Italy

Strategic Achievements

• Pioneered SRP® Vaccine Technology in multiple livestock sectors.
• Acquired Epitopix in the U.S., enhancing SRP® capabilities and North American footprint.
• Established One of Europe’s Largest Animal Health R&D Centers at Novio Tech Campus.
• Launched the GOVAXX® Brand to address emerging disease threats with global solutions.

Vaxxinova International B.V. continues to lead the way in preventive veterinary health with science-driven innovation, global reach, and a firm commitment to animal welfare and food safety.